Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ISRCTN10574179) titled 'Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema' on Feb. 9.
Study Type: Interventional
Study Design:
Interventional non randomized (Efficacy, Safety)
Primary Sponsor: Astria Therapeutics, Inc (USA)
Condition:
Hereditary angioedema
Haematological Disorders
Intervention:
Adult participants will receive one of three dosing regimens:
Regimen 1: Participants will receive 600 mg of navenibart (STAR-0215) via subcutaneous injection every 3 months.
Regimen 2: Participants will receive 300 mg of navenibart (STAR-0215) via subcutaneous injection every 3 months.
Regimen 3: Participants will receive...